课题基金 / 基金详情

A Novel Recombinant Protein Vaccine Against Ricin Toxin

A Novel Recombinant Protein Vaccine Against Ricin Toxin
一种新型重组蛋白抗蓖麻毒素疫苗
批准号:
6862775
负责人:
ELLEN S VITETTA
金额:
$67.88万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-09-15 至 2007-02-28

项目摘要

项目成果

ELLEN S VITETTA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Ricin is a highly lethal toxin produced by castor beans. It is readily available, easy to make, and stockpile. Ricin has a long history of use in espionage and warfare with a documented 750 cases of intoxication. Ricin is classified by the CDC as a Class B biothreat. In the 1990s, the U.S. Military became interested in developing a vaccine against ricin after obtaining information that this toxin was being stockpiled by terrorist organizations. A ricin toxoid is protective in primates, but it is quite toxic and did not receive FDA approval. We have generated three recombinant mutants of ricin's A chain which are devoid of both vascular leak activity and enzymatic activity in mice. When injected i.m., these mutants protect mice against very large doses of injected ricin. Our goal is to develop one of these mutants into an inexpensive, safe, effective, stable, and "user-friendly" vaccine which can be administered to large groups of people. The specific Aims of this proposal are: 1) to optimize production, purification, formulation and stability of the vaccine. 2) to determine whether the vaccine will protect mice against aerosolized as well as intraperitoneal (i.p.) ricin challenge and if so, the best method of immunization (i.m., oral, or intranasal) to protect animals for the longest period of time and 3) to produce a small good laboratory practice (GLP) batch of the best candidate vaccine and use the best route of administration to immunize six adult baboons (three males and three females). When these three aims are completed, the vaccine should be ready for acute toxicology studies in two species and scale-up for Phase 1 clinical trials in humans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A novel vaccine to prevent HCV infection and hence liver cancer
  • 批准号:
    7943947
  • 项目类别:
  • 资助金额:
    $62.0万
  • 财政年份:
    2009
  • 负责人:
    ELLEN S VITETTA
  • 依托单位:
A novel vaccine to prevent HCV infection and hence liver cancer
  • 批准号:
    7852639
  • 项目类别:
  • 资助金额:
    $68.37万
  • 财政年份:
    2009
  • 负责人:
    ELLEN S VITETTA
  • 依托单位:
PHASE 1 STUDY OF SAFETY & IMMUNOGENICITY OF AN ALUM-FORMULATED RECOMBINANT RICIN
  • 批准号:
    7475286
  • 项目类别:
  • 资助金额:
    $32.17万
  • 财政年份:
    2007
  • 负责人:
    ELLEN S VITETTA
  • 依托单位:
PHASE 1 STUDY OF SAFETY & IMMUNOGENICITY OF AN ALUM-FORMULATED RECOMBINANT RICIN
  • 批准号:
    7213715
  • 项目类别:
  • 资助金额:
    $30.77万
  • 财政年份:
    2007
  • 负责人:
    ELLEN S VITETTA
  • 依托单位:
海外基金